A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors

Cell Cycle

Volumn 10, Issue 6, 2011, Pages 963-970

  Massard, Christophe ^a   Soria, Jean Charles ^a   Anthoney, D Alan ^b   Proctor, A ^b   Scaburri, Angela ^c   Pacciarini, Maria Adele ^c   Laffranchi, Bernard ^c   Pellizzoni, Cinzia ^d   Kroemer, Guido ^a,e,f,g,h   Armand, Jean Pierre ^a   Balheda, Rastilav ^a   Twelves, Christopher J ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c NERVIANO MEDICAL SCIENCES   (Italy)

^d Accelera Srl   (Italy)

^e Institut Gustave Roussy   (France)

^f CENTRE DE RECHERCHE DES CORDELIERS   (France)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Cancer; CDK; Cell cycle; Hepatic failure

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR; PHA 793887; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CLINICAL ARTICLE; DIARRHEA; DISEASE ACTIVITY; DIZZINESS; DRUG DOSE ESCALATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HERPES SIMPLEX; HERPES VIRUS INFECTION; HUMAN; HYPOTENSION; LETHARGY; LIVER FAILURE; LIVER TOXICITY; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 79952640188     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.6.15075     Document Type: Article

References (16)

1. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001; 222-31. (Pubitemid 33741897)
2. Dickson MA, Schwartz GK. Development of cell cycle inhibitors for cancer therapy. Curr Oncol 2009; 36-43.
3. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009; 153-66.
4. Satyanarayana A, Kaldis P. Mammalian cell cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene 2009; 2925-39.
5. Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009; 547-66.
6. Brasca MG, Albanese C, Alzani R, Amici R, Avanzi N, Ballinari D, et al. Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing. Bioorg Med Chem 2010; 1844-53.
7. Alzani R, Pedrini O, Albanese C, Ceruti R, Casolaro A, Patton V, et al. Therapeutic efficacy of the pan-cdk inhibitor PHA-793887 in vitro and in vivo in engraftment and high-burden leukemia models. Exp Hematol 2010; 2:259-69.
8. Locatelli G, Bosotti R, Ciompi M, Brasca MG, CalogeroR, Mercurio C, et al. Transcriptional analysis of an E2F gene signature as a biomarker of activity of the Cdk inhibitor PHA-793887 in tumor and skin biopsies from a Phase I clinical study. Mol Cancer Therapeutics 2010; 1265-73.
9. Therasse P, Arbuck S, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 205-16. (Pubitemid 30099779)
10. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006; 1770-83. (Pubitemid 46628473)
11. Senderowicz AM. The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01. Oncologist 2002; 7:12-9.
12. Benson C, White J, De Bono J, O'Donnell A, Raynaud F, Cruickshank C, et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 2007; 29-37. (Pubitemid 46094635)
13. Loriot Y, Perlemuter G, Malka D, Penault-Llorca F, Boige V, Deutsch E, et al. Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy. Nat Clin Pract Oncol 2008; 268-78. (Pubitemid 351594143)
14. Blagosklonny MV, Pardee AB. Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res 2001; 61:4301-5. (Pubitemid 32685747)
15. Blagosklonny MV. Flavopiridol, an inhibitor of transcription: implications, problems and solutions. Cell Cycle 2004; 3:1537-42. (Pubitemid 40521407)
16. Blagosklonny MV, Darzynkiewicz Z. Why Iressa failed: toward novel use of kinase inhibitors. Cancer Biol Ther 2003; 2:137-40.